News

Neuroene Therapeutics has been awarded a Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The award supports Neuroene’s ongoing research and development of a novel class of well-tolerated compounds protects and ameliorates mitochondrial and neurological diseases.

Neuroene’s lead antiseizure drug (ASD) candidate has demonstrated broad-spectrum antiseizure activity in several animal models of pharmacoresistant seizures and Parkinson’s disease, showcasing its potential both as a fast-acting rescue agent and long-term chronic therapeutic. Intriguingly, the compound’s stability offers significant advantages for long-term storage and stockpiling in case of public health emergencies or bio-incidents.

By Alex Keown
June 8, 2023

This article is sponsored by Noble Life Sciences, a Maryland-based preclinical CRO with distinct expertise in the cell and gene therapy space. Reach out or request a quote to see how they can support your business.

Contract research organizations (CROs) are an essential key to a thriving life sciences ecosystem. Maryland is home to multiple CROs that provide broad support to the development of therapeutics across a broad spectrum of disease indications.

Maryland health technology company developing innovative medicine solutions to promote more personalized care

COLUMBIA, Md. (June 14, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a recent Seed Funds investment of $250,000 into Aidar Health, Inc., a health technology and digital medicine company. TEDCO’s Seed Funds invest in early-stage, technology and life sciences companies and provide access to gap financing.

Addimmune will build upon the success of American Gene Technologies Phase 1 HIV clinical trial, accelerating the clinical development with dedicated investment and singular focus on HIV.

American Gene Technologies, a clinical-stage biotechnology company based in Rockville, Maryland, is launching a new company — Addimmune — to continue to develop gene and cell therapy technologies to cure HIV. Addimmune will focus solely on advancing an HIV cure, building upon more than a decade of work by AGT that led to a successful Phase 1 HIV gene and cell therapy clinical trial.

Addimmune aims to create tremendous benefits for HIV patients, payers, and the public. Its gene therapy technology has the power to transform millions of lives. The new company’s name represents a fusion of two fundamental concepts: using gene and cell therapy to add new capacity to the human T cell to create an improved immune system to fight HIV.

Maryland biotechnology company creating methods for more efficient and reliable research

COLUMBIA, Md. (June 8, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a recent State Small Business Credit Initiative (SSBCI) investment of $300,000 into Nanocrine, a biotechnology company.

“Without a steady and reliable foundation, research can be unreliable and unpredictable,” said Patrick Calhoun, president and chief science officer of Nanocrine. “Unfortunately, this is where many researchers are when studying living cells; many surfaces that cells interact with are uncharacterized or not made with appropriate lab-specific protocols—Nanocrine is working to change this and advance the scientific research and exploration of living cells.”

New agreement will allow more collaboration to advance technology and life sciences innovations across the state

COLUMBIA, Md. (June 7, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced the signing of a Partner Intermediary Agreement (PIA) with the National Cancer Institute Technology Transfer Center (NCI TTC).

“NCI and TEDCO have collaborated for more than a decade on a variety of initiatives to bring the latest advancements in cancer research and technology to the public through Maryland businesses. These collaborations have helped create a thriving innovation ecosystem that benefits both patients and the economy,” said Tom Stackhouse, PhD, director, NCI TTC.
This agreement will codify the relationship between NCI and TEDCO, allowing the two organizations to help promote and foster more opportunities for Maryland’s life sciences community to work together with NCI on cooperative research.

Recently recognized as a Great Place to Work in the US for the second consecutive year, PQE Group, the woman-owned global consulting company, announces its mission towards innovation in the development of therapies for women’s health challenges.

A year after the foundation of GQC, an internal start-up of the Group focused on medical cannabis therapy solutions, Gilda D’Incerti – CEO and Founder of the company – is now dedicating her interest to FemTech (Female Technology) and the so-called SHEconomy: these primary market trends forecast tremendous growth in terms of profit and growth in the next decade, accelerating drug development for women’s health and well-being.

Maryland biotech company revolutionizing point-of-care testing for viruses and environmental toxins

COLUMBIA, Md. (June 7, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a $500,000 State Small Business Credit Initiative (SSBCI) investment into Hememics Biotechnologies, Inc., a biotechnology company. The investment came through TEDCO’s Venture Funds.

“I am extremely proud of what the company has achieved,” said John Warden, Jr., CEO and co-founder of Hememics Biotechnologies, Inc. “We have generated favorable results from more than 100,000 biosensor tests in the past nine months. The new funding will allow us to put the final touches on our product, and continue to develop early commercial customers.”
Hememics Biotechnologies, Inc., based in Gaithersburg, Md., is using graphene monolayer biosensors to revolutionize point-of-care testing for viruses and environmental toxins. The HemBox™, a cellphone-sized reader and chip platform, allows users to test for multiple viruses and toxins from samples as diverse as soil, water, saliva and blood.